Loading...
01/11 03:34
Loading...
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
The earnings call reveals financial strain, with a decrease in cash and rising R&D expenses. Supply chain challenges and enrollment issues further raise concerns. Although there is potential in the preeclampsia program, uncertainties in laboratory results and management's unclear responses about U.S. expansion contribute to a negative outlook. The lack of clear guidance and financial stability issues suggest a stock price decline of -2% to -8%.
Total combined cash and investments $37,300,000 (decreased from $44,100,000), a decrease of $6,800,000 year-over-year due primarily to net cash used to fund operations.
Current liabilities $4,700,000 (increased from $5,400,000), a decrease of $700,000 year-over-year.
Working capital $32,800,000 (decreased from $39,200,000), a decrease of $6,400,000 year-over-year due primarily to net cash used to fund operations.
Net cash used in operating activities $7,100,000 (increased from $6,700,000), an increase of $400,000 year-over-year due primarily to increased net loss, partially offset by changes in operating assets and liabilities.
Research and development expenses $5,700,000 (increased from $3,700,000), an increase of $2,000,000 year-over-year due primarily to cost increases from the continuation of the REMEDY two clinical trial, including global expansion and increased manufacturing development activity.
General and administrative expenses $2,500,000 (increased from $2,100,000), an increase of $400,000 year-over-year due primarily to additional non-cash share-based compensation expense.
Net other income $443,000 (decreased from $597,000), a decrease of $154,000 year-over-year driven by reduced interest income related to lower average marketable securities balances.
Preeclampsia Program Update: The Phase two investigator sponsored preeclampsia trial is close to identifying a target dose for Part 1b, with preliminary results expected between June and July.
DM199 in Preeclampsia: DM199 is the only novel agent currently being studied in pregnant women with preeclampsia, with a KOL event scheduled for May 28 to discuss the disease and treatment.
Stroke Program Enrollment: Enrollment for the stroke program is progressing steadily, with current participant enrollment between the 20th and 25th percentile mark for the interim analysis.
Global Expansion: The company is expanding its clinical trial for stroke globally, with a focus on high-enrolling sites.
Cash and Investments: As of March 31, 2025, DiaMedica reported total cash and investments of $37.3 million, down from $44.1 million at the end of 2024.
R&D Expenses: Research and development expenses increased to $5.7 million for Q1 2025, up from $3.7 million in Q1 2024, primarily due to the continuation of the REMEDY two clinical trial.
KOL Event: A key opinion leader call on preeclampsia is scheduled for May 28, aimed at educating stakeholders on the disease and current treatment options.
Future U.S. Expansion: Plans to expand the preeclampsia study to the U.S. in the future, contingent on the results of the current trials.
Regulatory Issues: The company anticipates needing regulatory clearance for future expansions of the preeclampsia study into the U.S. and globally, which could introduce delays and complexities.
Supply Chain Challenges: The timing of preliminary results from the preeclampsia trial is dependent on outside laboratories running various tests, which may lead to delays.
Financial Risks: The company reported a decrease in cash and investments from $44.1 million to $37.3 million, indicating potential financial strain as they continue to fund operations with a net cash used of $7.1 million in Q1 2025.
Competitive Pressures: The treatment of pregnancy complications, such as preeclampsia, remains outdated with no FDA-approved treatments, indicating a competitive landscape where the company must establish DM199 as a viable option.
Enrollment Challenges: While enrollment for the stroke program is progressing, the company is focusing on high-enrolling sites and may need to shut down underperforming sites, which could impact overall enrollment rates.
Operational Risks: The increase in R&D expenses to $5.7 million for Q1 2025, up from $3.7 million, suggests rising operational costs that could affect future financial stability.
Preeclampsia Program Update: The company is close to identifying a target dose for Part 1b of the Phase two trial, with preliminary results expected between June and July 2025.
KOL Event: DiaMedica will sponsor a preeclampsia key opinion leader call on May 28, 2025, to educate stakeholders on preeclampsia and the current state of treatment.
Stroke Program Enrollment: Enrollment is progressing steadily, with current participation at the 20th to 25th percentile mark for the interim analysis.
Interim Analysis Guidance: The interim analysis for the first 200 participants in the stroke program is expected to be completed in the first half of 2026.
Cash Runway: Current cash and investments provide a runway into Q3 2026.
R&D Expense Outlook: R&D expenses are expected to moderately increase in future periods due to ongoing clinical trials.
G&A Expense Outlook: G&A expenses are expected to remain steady in future periods.
Net Cash Used in Operations: Net cash used in operating activities for Q1 2025 was $7.1 million, up from $6.7 million in Q1 2024.
Total Cash and Investments: $37,300,000 as of 03/31/2025, down from $44,100,000 as of 12/31/2024.
Current Liabilities: $4,700,000 as of 03/31/2025.
Working Capital: $32,800,000 as of 03/31/2025, down from $39,200,000 as of 12/31/2024.
Net Cash Used in Operating Activities: $7,100,000 for Q1 2025, compared to $6,700,000 for Q1 2024.
Research and Development Expenses: $5,700,000 for Q1 2025, up from $3,700,000 for Q1 2024.
General and Administrative Expenses: $2,500,000 for Q1 2025, up from $2,100,000 for Q1 2024.
Net Other Income: $443,000 for Q1 2025, down from $597,000 for Q1 2024.
The earnings call reveals a mixed sentiment. While there is progress in clinical trials and a strong cash position due to private placement, increased expenses and net losses are concerning. The Q&A section highlights positive drug safety feedback and trial progression but lacks specifics on enrollment rates, indicating potential uncertainties. The absence of new partnerships or shareholder return plans further tempers enthusiasm. Given these factors, the stock price is likely to remain stable, suggesting a neutral sentiment.
The earnings call reveals mixed elements: increased R&D and G&A expenses leading to higher net losses, but also a promising outlook on clinical trials and a strong cash position post-private placement. The Q&A highlights positive sentiment towards leadership and program potential, yet some concerns over enrollment and lack of specific guidance. These factors balance out to a neutral sentiment, with no strong catalysts for significant stock movement in either direction over the next two weeks.
The earnings call reveals financial strain, with a decrease in cash and rising R&D expenses. Supply chain challenges and enrollment issues further raise concerns. Although there is potential in the preeclampsia program, uncertainties in laboratory results and management's unclear responses about U.S. expansion contribute to a negative outlook. The lack of clear guidance and financial stability issues suggest a stock price decline of -2% to -8%.
The earnings call highlighted several risks including financial, operational, regulatory, and market challenges. Despite ongoing clinical trials and expansions, there's a decrease in cash and investments, increased R&D expenses, and no share repurchase program, indicating potential liquidity issues. The Q&A session revealed uncertainties in regulatory timelines and expansion plans. These factors suggest a negative sentiment, likely leading to a stock price decrease of -2% to -8% over the next two weeks.
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
